Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gastroenterology

• Publication date

  2014-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.gastro.2014.02.036PMID 24582714
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DMS triggers apoptosis associated with the inhibition of SPHK1/NF-κB activation and increase in intracellular Ca2+ concentration in human cancer cells

  2013cited by this paper
• Clinical implications of chronic hepatitis E virus infection in heart transplant recipients.

  2013cited by this paper
• Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review

  2013cited by this paper
• Ribavirin treatment of acute and chronic hepatitis E: a single‐centre experience

  2013cited by this paper
• Virus–drug interactions—molecular insight into immunosuppression and HCV

  2012cited by this paper
• Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients

  2012cited by this paper
• Cyclophilin A and viral infections

  2012cited by this paper
• Hepatitis E.

  2012cited by this paper
• Mycophenolic acid augments interferon‐stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo

  2012cited by this paper
• Adaptation of a Genotype 3 Hepatitis E Virus to Efficient Growth in Cell Culture Depends on an Inserted Human Gene Segment Acquired by Recombination

  2012cited by this paper
• Hepatitis E.

  2012cited by this paper
• Chronic Hepatitis E in Heart Transplant Recipients

  2012influential reference
• Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus–host recombinant

  2011cited by this paper
• Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants.

  2011influential reference
• Viral hepatitis: Ciclosporin versus tacrolimus for HCV transplant recipients

  2011cited by this paper
• Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection

  2011cited by this paper
• The molecular epidemiology of hepatitis E virus infection.

  2011cited by this paper
• Glucocorticosteroids increase cell entry by hepatitis C virus.

  2010cited by this paper
• Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon‐α

  2010cited by this paper
• Hepatitis B Virus (HBV) Surface Antigen Interacts with and Promotes Cyclophilin A Secretion: Possible Link to Pathogenesis of HBV Infection

  2010cited by this paper
• Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A

  2009cited by this paper
• Cyclophilin A interacts with influenza A virus M1 protein and impairs the early stage of the viral replication

  2009cited by this paper
• Hepatitis E virus and chronic hepatitis in organ-transplant recipients.

  2008cited by this paper
• Impact of Steroids on Hepatitis C Virus Replication in Vivo and in Vitro

  2007cited by this paper
• Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression.

  2007cited by this paper
• Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir.

  2007cited by this paper
• Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA‐matched sibling donor

  2006cited by this paper
• Mycophenolic Acid 12‐h Trough Level Monitoring in Renal Transplantation: Association with Acute Rejection and Toxicity

  2006cited by this paper
• Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha.

  2006cited by this paper
• Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

  2005cited by this paper
• Acute viral E hepatitis with chronic liver disease (autoimmune hepatitis).

  2005cited by this paper
• Evolution of tacrolimus blood levels and concentration‐dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation

  2005cited by this paper
• Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.

  2005cited by this paper
• Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

  2003cited by this paper
• Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA.

  2002cited by this paper
• Long-term outcome of hepatitis C infection after liver transplantation.

  1996cited by this paper
• A longitudinal analysis of hepatitis C virus replication following liver transplantation.

  1996cited by this paper
• Hepatitis E.

  1994cited by this paper
• Specific incorporation of cyclophilin A into HIV-1 virions

  1994cited by this paper
• Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals.

  1984cited by this paper

• Update on the molecular and cellular biology of hepatitis E virus and therapeutic opportunities.

  2026cites this paper
• Can Adoptive Immunotherapy With Hepatitis E Virus (HEV)–Specific T Cells Address the Unmet Need in Refractory Chronic HEV Infection?

  2025cites this paper
• The high burden of HEV infection in solid organ transplant recipients

  2025cites this paper
• AMPK activation by hepatitis E virus infection inhibits viral replication through attenuation of autophagosomes and promotion of innate immunity

  2025cites this paper
• Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants

  2025cites this paper
• SARS-CoV-2 infection enhancement by amphotericin B: implications for disease management

  2025cites this paper
• Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model

  2025cites this paper
• Chronic hepatitis E: The neglected liver killer.

  2025cites this paper
• The Differential Effects of Immunosuppressants on Hepatitis E Virus Replication and the Triggered Inflammatory Responses in Macrophages

  2025cites this paper
• Interference without interferon: interferon-independent induction of interferon-stimulated genes and its role in cellular innate immunity

  2024cites this paper
• S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)

  2024cites this paper
• Hepatitis E virus: from innate sensing to adaptive immune responses

  2024cites this paper
• Relevance of Tacrolimus Trough Concentration and Hepatitis E virus Genetic Changes in Kidney Transplant Recipients With Chronic Hepatitis E

  2024cites this paper
• Optimization of immunosuppression strategies for the establishment of chronic hepatitis E virus infection in rabbits

  2024influential citation
• Hepatitis E virus infects human testicular tissue and Sertoli cells

  2024cites this paper
• Hepatitis E Virus (HEV) Infection Among Immunocompromised Individuals: A Brief Narrative Review

  2024cites this paper
• Computer-aided drug discovery of natural antiviral metabolites as potential SARS-CoV-2 helicase inhibitors

  2024cites this paper
• Viral hepatitis E: Clinical manifestations, treatment, and prevention

  2024cites this paper
• Host-Targeting Antivirals for Chronic Viral Infections of the Liver.

  2024cites this paper
• Network controllability analysis reveals the antiviral potential of Etravirine against hepatitis E virus infection

  2024cites this paper
• Incidence and risk factors of de novo hepatitis E virus infection after receiving liver transplantation

  2024cites this paper
• Efficacy and safety of calcineurin inhibitors (CNIs) for septic patients in ICU: a cohort study from MIMIC database

  2024cites this paper
• Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms

  2023cites this paper
• Diagnostic and management strategies for chronic hepatitis E infection

  2023cites this paper
• mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES Study (Chronic Hepatitis E Screening in patients with immune impairment and increased transaminases levels)

  2023cites this paper
• Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus

  2023cites this paper
• Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir

  2023influential citation
• The Re-Emergence of Hepatitis E Virus in Europe and Vaccine Development

  2023cites this paper
• Hepatitis E Virus: Epidemiology, Clinical Aspects, and Its Significance as a Major Pregnancy Risk

  2023cites this paper
• The hepatitis E virus ORF1 hypervariable region confers partial cyclophilin dependency

  2023cites this paper
• Early ribavirin for hepatitis E virus infection in patients receiving immunosuppressive therapy: a retrospective, observational study

  2023cites this paper
• Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy

  2022cites this paper
• A small animal model of chronic hepatitis E infection using immunocompromised rats

  2022cites this paper
• The role of cyclophilins in viral infec and the immune response.

  2022cites this paper
• A Less Common Cause of Acute Hepatitis in Kidney Transplant Recipients: A Case Series.

  2022cites this paper
• Chronic hepatitis E: advancing research and patient care.

  2022cites this paper
• Hepatitis E seroprevalence, cases and management in a large German centre for liver transplantation

  2022cites this paper
• Enhanced Production of Mycophenolic Acid from Penicillium brevicompactum via Optimized Fermentation Strategy

  2022cites this paper
• Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients

  2022cites this paper
• Recapitulating hepatitis E virus–host interactions and facilitating antiviral drug discovery in human liver–derived organoids

  2022cites this paper
• Transfusion-transmitted hepatitis E: What we know so far?

  2022cites this paper
• Hepatitis E Virus Infection, a Risk for Liver Transplant Recipients in Sweden

  2022cites this paper
• Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients

  2022cites this paper
• Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States

  2022cites this paper
• Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery

  2021cites this paper
• Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin α1

  2021cites this paper
• The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer

  2021cites this paper
• Production of Mycophenolic Acid by a Newly Isolated Indigenous Penicillium glabrum

  2021cites this paper
• Hepatitis E Virus Infection—Immune Responses to an Underestimated Global Threat

  2021cites this paper
• Hepatitis E Virus Immunopathogenesis

  2021cites this paper
• Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling.

  2021cites this paper
• Hepatitis E: vom akut-auf-chronischen Leberversagen bis zur chronischen Hepatitis E

  2021cites this paper
• Hepatitis E Virus—Current Developments in Antiviral Strategies

  2021cites this paper
• Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health

  2020cites this paper
• The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections

  2020cites this paper
• Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections

  2020cites this paper
• Noninvasive models for predicting poor prognosis of chronic HBV infection patients precipitating acute HEV infection

  2020cites this paper
• Hepatitis E Is a Rare Finding in Liver Transplant Patients With Chronic Elevated Liver Enzymes and Biopsy-Proven Acute Rejection.

  2020cites this paper
• Hepatitis E Infections in Transplants

  2020cites this paper
• Japonicone V, a sesquiterpene lactone derivative from the flowers of Inula japonica, inhibits hepatitis E virus replication by targeting virus-associated autophagy

  2020cites this paper
• Guanylate-binding protein 2 orchestrates innate immune responses against murine norovirus and is antagonized by the viral protein NS7

  2020cites this paper
• Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients

  2020cites this paper
• On the Host Side of the Hepatitis E Virus Life Cycle

  2020cites this paper
• Ribavirin long-term treatment for chronic hepatitis E virus infection in a liver transplant recipient.

  2020cites this paper
• Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro

  2020cites this paper
• Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study.

  2020cites this paper
• A Review of the Diagnosis and Management of Hepatitis E

  2020cites this paper
• Treatment for chronic hepatitis E virus infection: A systematic review and meta‐analysis

  2020cites this paper
• High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2

  2020cites this paper
• ERKRANKUNGEN DER VERDAUUNGSORGANE

  2020cites this paper
• Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation.

  2020cites this paper
• Impact of Genetic Variants in Inosine Triphosphate Pyrophosphatase and Interferon-λ4 on Natural History, Treatment Response and Ribavirin Pharmacology in Hepatitis C Virus Infection

  2020cites this paper
• Gut microbiome and multiple sclerosis: New insights and perspective.

  2020cites this paper
• Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment

  2020cites this paper
• Clinical features and determinants of chronicity in hepatitis E virus infection

  2019cites this paper
• Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients.

  2019cites this paper
• Viral Hepatitis: Acute Hepatitis

  2019cites this paper
• Cell Culture Models for Hepatitis E Virus

  2019cites this paper
• Clinical presentations of Hepatitis E: A clinical review with representative case histories

  2019cites this paper
• Sero-Detection of Hepatitis E Virus (HEV) among Pregnant Women Attending Khartoum North Hospital in Khartoum State

  2019cites this paper
• Hepatitis E Virus Infection and the Treatment

  2019cites this paper
• Antiviral Candidates for Treating Hepatitis E Virus Infection

  2019cites this paper
• A Review of Acute Viral Hepatitides Including Hepatitis E

  2019cites this paper
• Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections

  2019cites this paper
• Chronic hepatitis E after kidney transplantation with an antibody response suggestive of reinfection: a case report

  2019cites this paper
• Emerging New Therapies for Viral Hepatitis

  2019cites this paper
• Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin

  2019cites this paper
• Screening of novel drugs for inhibiting hepatitis E virus replication.

  2019cites this paper
• Hepatitis E Virus Drug Development

  2019cites this paper
• The Interplay between Host Innate Immunity and Hepatitis E Virus

  2019cites this paper
• Stem Cell-Derived Hepatocyte-Like Cells as Model for Viral Hepatitis Research

  2019cites this paper
• Stem Cell-Derived Culture Models of Hepatitis E Virus Infection.

  2019influential citation
• Clinical Epidemiology of Chronic Liver Diseases

  2019cites this paper
• Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment.

  2019cites this paper
• RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection.

  2019cites this paper
• Recent Advances Towards the Development of a Potent Antiviral Against the Hepatitis E Virus

  2018cites this paper
• Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report

  2018cites this paper
• Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients

  2018cites this paper
• Dosing ribavirin in hepatitis E‐infected solid organ transplant recipients

  2018cites this paper
• Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity

  2018influential citation